2020•International Journal of Clinical OncologyRequires access

Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab

Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa

Open publisher page 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Axitinib, Nivolumab, Renal cell carcinoma, Internal medicine, Oncology, Adverse effect, Regimen

Back to paper search Browse research topics Original source

Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab — Research Paper | ScholarLens